p16 status and choice of chemotherapy in the KEYNOTE-040 study

Lancet. 2019 Oct 12;394(10206):1321-1322. doi: 10.1016/S0140-6736(19)31261-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Cetuximab
  • Docetaxel*
  • Humans
  • Methotrexate
  • Squamous Cell Carcinoma of Head and Neck*

Substances

  • Antibodies, Monoclonal, Humanized
  • Docetaxel
  • pembrolizumab
  • Cetuximab
  • Methotrexate